
Opinion|Videos|November 15, 2024
Addressing Payer Coverage Challenges
Key Takeaways
- Quadruplet regimens face payer coverage challenges, including prior authorization and high patient costs, impacting access to treatment.
- Providers address these challenges through proactive payer communication and presenting clinical evidence to support regimen efficacy.
Panelists discuss how they navigate challenges with payer coverage for quadruplet regimens in multiple myeloma treatment, including strategies they employ to address insurance denials or restrictions, such as providing clinical justification, leveraging recent trial data, and collaborating with financial assistance programs to ensure patients can access optimal therapy despite potential coverage difficulties.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- As a provider, have you noticed any difficulties regarding payer coverage for quadruplet regimens? If so, how have you addressed these challenges?
Advertisement
Related to this article

Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.

A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Community Pharmacists Guide Patients New to Glucose Monitoring
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5


